Bristol and Glaxo’s oncology deals vault into the top five
Two huge up-front fees this week, for an anti-Tigit MAb and an antibody-drug conjugate, show that early-stage oncology assets are still hot.
Biogen’s Sage advice amounts to $1.5bn
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Biogen pays $560m for an unproven Parkinson’s mechanism
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Crunch time for the new Parkinson’s hopes
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
